Skip to main content

and
  1. No Access

    Article

    Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma

    We identified a discrete number of microRNAs differentially expressed in benign or malignant mesothelial tissues. We focused on mir-145 whose levels were significantly downregulated in malignant mesothelial ti...

    M Cioce, F Ganci, V Canu, A Sacconi, F Mori, C Canino, E Korita, B Casini in Oncogene (2014)

  2. No Access

    Article

    Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells

    Mutant p53 proteins are expressed at high frequency in human tumors and are associated with poor clinical prognosis and resistance to chemotherapeutic treatments. Here we show that mutant p53 proteins downregu...

    S Masciarelli, G Fontemaggi, S Di Agostino, S Donzelli, E Carcarino, S Strano in Oncogene (2014)

  3. No Access

    Article

    SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells

    Here we show that pemetrexed-treated mesothelioma cells undergo accelerated senescence. This is characterized by the secretion of proinflammatory and mitogenic cytokines, reminiscent of an SASP (senescence-ass...

    C Canino, F Mori, A Cambria, A Diamantini, S Germoni, G Alessandrini in Oncogene (2012)

  4. No Access

    Article

    Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulation

    Several epidemiological studies have shown that high levels of melatonin, an indolic hormone secreted mainly by the pineal gland, reduce the risks of develo** cancer, thus suggesting that melatonin triggers ...

    R Santoro, M Marani, G Blandino, P Muti, S Strano in Oncogene (2012)

  5. No Access

    Article

    Autonomic cardiovascular function and baroreflex sensitivity in patients with cervical dystonia receiving treatment with botulinum toxin type A

    To investigate possible changes in autonomic cardiovascular regulation and cardiopulmonary baroreflex sensitivity in patients with primary cervical dystonia receiving chronic treatment with botulinum toxin typ...

    D. Tiple, S. Strano, C. Colosimo, G. Fabbrini, G. Calcagnini in Journal of Neurology (2008)

  6. No Access

    Article

    Mutant p53: an oncogenic transcription factor

    Inactivation of tumor-suppressor genes is one of the key hallmarks of a tumor. Unlike other tumor-suppressor genes, p53 is inactivated by missense mutations in half of all human cancers. It has become increasi...

    S Strano, S Dell'Orso, S Di Agostino, G Fontemaggi, A Sacchi, G Blandino in Oncogene (2007)

  7. No Access

    Article

    S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation

    The p53 paralogues p73, p63 and their respective truncated isoforms have been shown to be critical regulators of developmental and differentiation processes. Indeed, both p73- and p63-deficient mice exhibit se...

    E Lapi, A Iovino, G Fontemaggi, A R Soliera, S Iacovelli, A Sacchi, G Rechavi in Oncogene (2006)

  8. No Access

    Article

    Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

    Mutations in the TP53 tumor suppressor gene are the most frequent genetic alteration in human cancers. These alterations are mostly missense point mutations that cluster in the DNA binding domain. There is growin...

    G Bossi, E Lapi, S Strano, C Rinaldo, G Blandino, A Sacchi in Oncogene (2006)